Combination therapy: Intermittent sorafenib with bevacizumab yields activity and decreased toxicity

J. M. Lee, G. A. Sarosy, C. M. Annunziata, N. Azad, L. Minasian, H. Kotz, J. Squires, N. Houston, E. C. Kohn

Research output: Contribution to journal › Article › peer-review

57 Scopus citations

Fingerprint

Dive into the research topics of 'Combination therapy: Intermittent sorafenib with bevacizumab yields activity and decreased toxicity'. Together they form a unique fingerprint.

Medicine & Life Sciences